GlassScriptPhysician profile
Eric Stephen Kroner
NPI 1730149998
$1,469.79
in general payments reported to CMS, 2019-2025
28 companies · $356 in 2025
The $356 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $25.00 · 2022: $33.31 · 2024: $1,055 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,411.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $164.20 | 2024 | |
| Globus Medical, INC. | $147.85 | 2025 | Senza |
| Gilead Sciences, INC. | $130.63 | 2024 | Trodelvy |
| Abbvie INC. | $128.90 | 2024-2025 | |
| Neurelis, INC. | $123.50 | 2025 | Valtoco |
| Alexion Pharmaceuticals, INC. | $78.12 | 2024 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $62.76 | 2024 | Iclusig, Alunbrig |
| Daiichi Sankyo INC. | $58.74 | 2024 | Enhertu |
| Celgene Corporation | $49.36 | 2024 | Reblozyl |
| Glaxosmithkline, LLC. | $47.03 | 2022-2024 | Ojjaara |
| Beigene USA, INC. | $44.83 | 2024 | Brukinsa |
| Eisai INC. | $42.89 | 2024 | |
| Genmab U.S., INC. | $42.45 | 2024 | Epkinly |
| Regeneron Healthcare Solutions, INC. | $37.65 | 2024 | Libtayo |
| Incyte Corporation | $27.91 | 2024 | Pemazyre, Monjuvi, Jakafi |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $25.98 | 2024 | Xpovio |
| Actuated Medical, INC. | $25.00 | 2021 | |
| Mirati Therapeutics, INC. | $23.77 | 2024 | Krazati |
| Tersera Therapeutics LLC | $22.51 | 2024 | Quzyttir |
| Janssen Biotech, INC. | $22.51 | 2024 | Erleada, Akeega |
| Pharmacosmos Therapeutics INC. | $22.13 | 2024 | Monoferric |
| Pharmaessentia USA Corporation | $21.98 | 2024 | Besremi |
| Lilly USA, LLC | $21.84 | 2024 | Retevmo, Jaypirca, Verzenio |
| Spr Therapeutics, INC | $21.41 | 2025 | Sprint Pns System |
| Pfizer INC. | $20.66 | 2024 | |
| Genentech USA, INC. | $19.17 | 2024 | Lunsumio, Polivy, Columvi |
| E.R. Squibb & Sons, L.L.C. | $19.15 | 2024 | Opdivo |
| Avanos Medical | $16.86 | 2025 | Standard Rf Disposables |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Kroner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.